Episode Details
Back to Episodes
Pharmaceutical Executive Daily: FDA Approves Palynziq and Sogroya
Published 2 months, 2 weeks ago
Description
In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older, Sogroya becomes the first and only weekly long-acting growth hormone approved for pediatric use, and experts examine how real-world data strengthens natural history disease research.